Jersey City-based Scynexis Inc., a biotechnology company delivering therapies for difficult-to-treat and often life-threatening infections, said Thursday it completed patient enrollment, ahead of schedule, in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection.